Penn Spinout Verismo Therapeutics Receives FDA Clearance of Investigational New Drug Application for SynKIR-110™, a KIR-CAR T Cell Immunotherapy Candidate
Verismo plans to begin enrolling patients in the first quarter of 2023 at the initial clinical site, the Hospital of the University of Pennsylvania.
The combined company, which is expected to operate under the name Carisma Therapeutics Inc., will focus on advancing Carisma’s proprietary cell therapy platform.
This new approach to CAR-T therapy will involve mRNA therapy that directs cells in the body to make proteins to prevent or fight disease.
B.PHL Innovation Festival: PCIV Startup VasoWatch LLC and PCI I-Corps Participant Viora Health Featured
The event, which served as a gathering place for local and global creatives, entrepreneurs, leaders, students, and industry changemakers, featured some incredible Penn startups.
Their innovative work was recognized by the Philadelphia Business Journal's PHL Inno initiative, which awards people 25 years and younger who are making an impact in the area’s startup ecosystem.
Penn Spinout Interius BioTherapeutics Is Developing Tools to Perform Cell and Gene Engineering Directly in the Human Body
The hope is that this new technology could simplify the process of CAR-T cell therapy and make gene therapy widely available as a one-time injection to a much larger number of patients.
PCI Startup SchoolSims Named One of the 100 Fastest Growing Companies in the Philadelphia Region by Philadelphia100® Forum
SchoolSims is an education company that offers technology-enhanced immersive learning solutions to leadership development for educational and other organizations.
Penn Spinout Verismo Therapeutics Announces Submission of Investigational New Drug Application to the FDA for KIR-CAR T-cell Immunotherapy Candidate
Pending regulatory approval, Verismo plans to use the drug in patients with mesothelin-expressing ovarian cancer, mesothelioma and cholangiocarcinoma.
Penn Gene-Editing Spinout iEcure Receives Rare Pediatric Disease Designation from FDA for Lead Drug Candidate
iEcure is developing the new drug candidate, GTP-506, as a treatment for a rare genetic condition caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia.
Philadelphia's innovation hub has seen explosive growth over the past several years, with significant expansions in manufacturing and research space for multiple companies.